A phase 2 clinical trial of the experimental drug daraxonrasib demonstrated a significant survival benefit for patients with advanced pancreatic cancer, with participants living twice as long as those receiving standard care. The results, published in the *Journal of Clinical Oncology* in April 2026, marked a rare breakthrough in a disease with a five-year survival rate of less than 10%. The drug, developed by biotech firm Virexia Pharmaceuticals, targets a specific genetic mutation linked to tumor growth, according to the study’s lead author, Dr. Elena Marquez of the University of California, San Francisco.
The trial involved 120 patients with metastatic pancreatic cancer who had exhausted conventional therapies. Those receiving daraxonrasib showed a median overall survival of 14.2 months, compared to 7.1 months for the control group. Researchers noted the drug’s ability to inhibit the RAS protein, a known driver of aggressive cancer progression. However, the study’s sample size and lack of a placebo group have prompted calls for larger, randomized trials to confirm the findings.
While the primary focus of the research was pancreatic cancer, preliminary data from preclinical models suggest the drug may also interfere with similar genetic pathways in lung, colon and ovarian cancers. Virexia’s chief scientific officer, Dr. Rajiv Mehta, stated in a press release that “the mechanism of action appears to be broadly applicable,” though he emphasized that human trials for these other cancers are still in early stages. The company has initiated a phase 1 trial for non-small cell lung cancer, with results expected in 2027.
The findings have drawn attention from regulatory bodies, including the U.S. Food and Drug Administration, which has granted daraxonrasib “breakthrough therapy” designation for pancreatic cancer. This status accelerates review processes but does not guarantee approval. Meanwhile, the National Cancer Institute has launched a separate study to evaluate the drug’s efficacy in combination with immunotherapy, a treatment approach that has shown mixed results in pancreatic cancer patients.
Clinical oncologists have expressed cautious optimism. Dr. Amina Khalid, a surgeon at Memorial Sloan Kettering Cancer Center, noted that “any improvement in survival for advanced pancreatic cancer is significant, but we must remain vigilant about potential side effects and resistance mechanisms.” The drug’s most common adverse effects reported in the trial included fatigue and gastrointestinal distress, though no life-threatening complications were recorded.
Virexia Pharmaceuticals has not yet disclosed pricing details for daraxonrasib, but industry analysts predict it could cost upwards of $150,000 per year, placing it among the most expensive cancer treatments. The company has pledged to work with insurers and patient advocacy groups to ensure accessibility, though no formal agreements have been announced. The drug’s potential impact on healthcare systems remains uncertain, given the high costs associated with cancer care in the United States and other developed nations.
The next critical step for daraxonrasib will be a phase 3 trial, which is expected to begin in early 2027. If successful, the drug could reshape treatment protocols for pancreatic cancer, a disease that claims over 40,000 lives annually in the U.S. Alone. For now, researchers caution that while the results are promising, they represent “a step forward, not a cure,” and emphasize the need for continued investment in cancer research and patient support programs.
